Synthesis and Optimization of the Docetaxel-Loaded and Durvalumab-Targeted Human Serum Albumin Nanoparticles, In Vitro Characterization on Triple-Negative Breast Cancer Cells
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Amer Chemical Soc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Triple-negative breastcancer (TNBC) tends to behave more aggressivelycompared to other breast cancer subtypes due to the lack of receptorsand its limited targeting therapy. In recent years, nanotechnologyadvancement has led to the development of various nanoparticle platformsfor the targeted treatment of cancers. Especially, HSA-NPs have specificadvantages such as biocompatibility, adjustable size during production,and relatively easy synthesis. In this study, HSA-NPs were encapsulatedwith docetaxel (DTX) and functionalized with polyethylene glycol (PEG),also becoming a targeting nanoplatform modified with durvalumab (DVL),and the whole nanostructure was well characterized. Subsequently,drug release studies and various in vitro cell culturestudies such as determining the cytotoxicity and apoptotic levelsof the nanoplatforms and PD-L1 using ELISA test were conducted onMDA-MB-468, MDA-MB-231, and MCF-7 cells. According to the results,HSA-DTX@PEG-DVL NPs showed better cytotoxicity compared to DTX inall the three cell lines. In addition, it was observed that the HSA-DTX@PEG-DVLNPs did not lead the cells to late apoptosis but were effective inthe early apoptotic stage. Moreover, the ELISA data showed a significantlyinduced PD-L1 expression due to the presence of DVL in the nanostructure,which indicates that DVL antibodies successfully bind to the HSA-DTX@PEG-DVLnanostructure.
Açıklama
Anahtar Kelimeler
Drug-Delivery, Pd-L1 Expression, Antibody, Adenocarcinoma, Nanocarriers, Chemotherapy, Therapy, Binding, System, Impact
Kaynak
Acs Omega
WoS Q Değeri
Q2
Scopus Q Değeri
Q1
Cilt
8
Sayı
29
